

SCIENTIFIC LETTER

About a rare case of hypoglycemia: Non-islet cell tumor hypoglycemia (NICTH)



A propósito de un caso raro de hipoglucemia: Hipoglucemia por tumor de células no islotes (NICTH)

Dear Editor:

Non-islet cell tumor hypoglycemia is a rare paraneoplastic syndrome associated with large benign/malignant tumors, due to an overproduction of Big-IGF2.¹ Below, we describe a case of this rare condition. An 83-year-old woman, with a previous history of type 2 diabetes mellitus (T2DM), dyslipidemia, depression and basal cell epithelioma resection, was admitted for further study of repetitive hypoglycemic events for the previous 3 months and 7 kg weight loss within the last year. She had a well-controlled T2DM (HbA1c 5.9%) on metformin 850 mg/daily. Her mother and 3 maternal cousins had been diagnosed with hepatocarcinoma. The physical examination was not relevant except for decreased vesicular murmur in the right lower hemithorax. Weight and body mass index were 52 kg and 24 kg/m² respectively. During a hypoglycemic episode the following results were found: blood glucose 37 mg/dl, C-peptide 0.09 ng/ml (0.81–3.85), insulin <0.50 μU/ml (3–25), anti-insulin antibody <5 U/ml (<5) and chromogranin A 59.8 ng/ml (19.4–98.1). A chest X-ray showed opacity in the lower right lobe (Fig. 1A). Chest CT scan showed a non-invasive well-defined mass sized 10 cm × 10 cm × 20 cm, displacing bronchial structures and a right pleural effusion with a maximum thickness of 15 mm. This was suggestive of a primary pleural tumor, being a solitary fibrous tumor (SFT) or mesothelioma the most plausible diagnostic options. NICTH was suspected and lab tests revealed: IGF2 510 ng/ml (350–1000), IGF1 <25 ng/ml (54.60–204.4), IGFBP3 1.43 ng/ml (2.2–4.5) and IGF2/IGF1 ratio 20.4 (<3). During the preoperative period, hypoglycemia was effectively prevented with a fractionated enriched diet, intravenous glucose infusion and prednisone 30 mg/daily. A 1850 g solid mass of 22.6 cm × 14.5 cm × 9.7 cm solid mass was resected via a right posterolateral thoracotomy (Fig. 1B). The microscopic examination revealed a well-defined proliferation with highly-cellular focal areas that alternate with paucicellular areas, edema, focal necrosis, moderate atypia and a mitotic index of 4 mitosis/10 high-power fields (Fig. 1C). Immunohistochemistry was positive for CD34, BCL2, CD99 and IGF1R establishing the diagnosis

of a non-invasive SFT (Fig. 1D and E). No radiological signs of disease recurrence were observed in the CT scan performed 2 months after surgery and glucose-lowering treatment (linagliptin/metformin 2.5/850 mg BID) was resumed due to poor glycemic control. She did not receive postoperative radiotherapy and the tumor did not show recurrence for the first year after surgery. Then, a minimal pleural thickening with progressive growth was observed and radical fractionated radiotherapy was administered (total dose 5750 cGy). There were no changes in glycemic control, T2DM treatment or hypoglycemic events during recurrence. In her last radiological control, 6 years after surgery, there were no signs of recurrence.

Non-islet cell tumor hypoglycemia is a rare cause of hypoglycemia, due to a tumor overproduction of pro-IGF-2 (Big-IGF2).¹ Tumors of mesenchymal or hepatic origin are the most common cause, but hypoglycemia has also been described in other benign and malignant tumors: fibrosarcomas, mesotheliomas, hemangiopericytoma, Lymphoma/Leukemia, gastrointestinal stromal tumor (GIST), yolk cell tumor, plasmocytoma, Leydig cell tumor, phylloides tumor of the breast and adrenocortical, pancreatic and medullary thyroid carcinoma.^{2,3} In a review, a total of 290 cases were identified in the literature between 1988 and 2013, hypoglycemia was the first manifestation in 48% of cases, age ranged from 2 to 87 years (mean 56.4), tumor diameter tended to be very large (between 10–20 cm) and there was no gender preference.² Other findings include hypokalemia and acromegaloid changes.² Normally IGF2 is limited to the vascular space in the form of high molecular weight complexes, 80% as ternary complexes (With IGFBP3 and acid-labile subunit), 20% as binary complexes (With IGFBP3) and very little as free IGF2. Abnormal forms of IGF2 (Big-IGF2) cannot form these complexes resulting in higher amounts of low molecular weight complexes and free forms of IGF2, that can cross the capillary membranes to interact with insulin receptors causing hypoglycemia by inhibiting gluconeogenesis, glycogenolysis, and ketogenesis.⁴ Additionally, IGF2 suppresses insulin, GH (with resultant low IGF1) and glucagon secretion.^{3–5} Solitary fibrous tumor, first described in 1870 by Wagner, is a rare soft tissue neoplasm, with an incidence of 0.2 per 100,000/year, that causes less than 5% of primary pleural tumors. It can also be found in other locations such as retroperitoneal, hepatic or pelvic locations. Typically, it is usually diagnosed in the 5th–6th decades, there is no sex preference and they are benign in most cases, although patients may recur and metastasize on occasions.⁶ They usually present with respiratory symptoms (cough, dyspnea, chest pain) and though one third of tumors are diagnosed incidentally. Hypo-




Figure 1 A: Preoperative thoracic chest x-ray. B: Macroscopic view of the resected tumor. C: Microscopic view. D: CD34 immunostaining. E: BCL2 immunostaining.

glycemia is present in only 4% of patients (Doege-Potter syndrome), although most of them have an overproduction of Big-IGF2.^{6,7} NICTH is suspected when other most frequent causes of hypoinsulinemic hypoglycemia (low insulin/C-peptide/proinsulin/betahydroxybutyrate levels), in the absence of a hypoglycemic agent, are ruled out. Typically, high IGF2/IGF1 ratio (>3), low IGF1 and normal to high IGF2 levels are the main biochemical features. In some cases, IGF2 could be low, but the presence of higher amounts of high molecular weight IGF2 (Big-IGF2) confirms the diagnosis. Of note, false positive IGF2/IGF1 ratio could be present in patients with malnutrition and sepsis and false negative in those with renal failure (renal failure is associated with low levels of IGFBP3 that can influence IGF1 and IGF2 levels). Transparietal puncture biopsy is not enough as a diagnostic procedure and a complete resection is needed with a further pathological evaluation and demonstration of positive immunostaining for CD34 and signal transducer and activator of transcription 6 (STAT6).^{7,8} Recently, NAB2-STAT6 fusion genes, that convert a transcriptional repressor (NAB2) into a transcriptional activator (NAB2-STAT6) have been proposed for the pathogenesis of SFT, leading to overexpression of early growth response 1 (EGR1) target genes (IGF2, H19, and RRAD).⁹ A decreased activity of the enzyme PCSK4 (Proprotein Convertase Subtilisin/Kexin Type 4) that impairs the processing of pro-IGF2 may also contribute to the overproduction of big IGF2.¹⁰ The prognosis is good, even in malignant forms, when a complete resection is achieved. If there is a case of recurrence, local radiotherapy can be

considered, but chemotherapy has very limited benefits.² Hypoglycemia in NICTH improves with corticosteroid treatment, glucagon infusions and recombinant growth hormone (rGH) have been used as well with favorable results, but diazoxide and somatostatin analogs are not useful.² Antibodies against both mature and pro IGF2, anti-IGF2 small interfering RNA and methods that enhance PCSK4 activity³ are therapies under investigation for the treatment of this rare form of hypoglycemia. In conclusion, based on this case report, NICTH should be suspected in patients with hypoglycemia of unclear etiology.

Financial support

The authors state that they have not received funding for carrying out this study.

References

1. de Groot JWB, Rikhof B, van Doorn J, Bilo HJG, Alleman MA, Honkoop AH, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. *Endocr Relat Cancer*. 2007;14:979-93.
2. Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. *J Clin Endocrinol Metab*. 2014;99:713-22.
3. Garla V, Sonani H, Palabindala V, Gomez-Sanchez C, Subauste J, Lien LF. Non-islet cell hypoglycemia: case series and review of the literature. *Front Endocrinol*. 2019;10:316.

4. Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, et al. Tumors IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. *Endocr Rev.* 2013;34:798–826.
5. Fukuda I, Asai A, Nagamine T, Harada T, Tanimura-Inagaki K, Hizuka N, et al. Levels of glucose-regulatory hormones in patients with non-islet cell tumor hypoglycemia: including a review of the literature. *Endocr J.* 2017;64:719–26.
6. Baldi GG, Stacchiotti S, Mauro V, Dei Tos AP, Gronchi A, Pastorino U, et al. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. *Clin Sarcoma Res.* 2013;3:4.
7. Thway K, Ng W, Noujaim J, Jones RL, Fisher C. The current status of solitary fibrous tumor: diagnostic features, variants, and genetics. *Int J Surg Pathol.* 2016;24:281–92.
8. Vogels RJC, Vlenterie M, Versleijen-Jonkers YMH, Ruijter E, Bekers EM, Verdijk MAJ, et al. Solitary fibrous tumor – clinicopathologic, immunohistochemical and molecular analysis of 28 cases. *Diagn Pathol.* 2014;9:224.
9. Robinson DR, Wu Y-M, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung Y-S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. *Nat Genet.* 2013;45:180–5.
10. Kawai S, Ariyasu H, Uraki S, Takeshima K, Morita S, Inaba H, et al. Imbalanced expression of IGF2 and PCSK4 is associated with overproduction of big IGF2 in SFT with NICTH: a pilot study. *J Clin Endocrinol Metab.* 2018;103:2728–34.

Roberto Sierra-Poyatos*, Jersey Cárdenas-Salas, Maite Ortega-Juaristi, Clotilde Vázquez-Martínez

Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

*Corresponding author.

E-mail address: roberto.sierra@quironsalud.es (R. Sierra-Poyatos).

<https://doi.org/10.1016/j.endinu.2020.07.008>
2530-0164/

© 2020 SEEN y SED. Published by Elsevier España, S.L.U. All rights reserved.

Doble tumor hipofisario corticotropo-tumor de células granulares: una asociación muy infrecuente



Concurrent corticotroph pituitary tumor and granular cell tumor: A very uncommon association

Sr. Editor:

El tumor de células granulares (TCG) pertenece al grupo de tumores de la hipófisis posterior (clasificación de la WHO de 2017)¹. Son tumores poco frecuentes, con la característica común de tener inmunohistoquímica positiva para el factor de transcripción tiroideo 1 (TTF-1), proteína S-100 y vimentina. La coexistencia con adenomas hipofisarios funcionantes es excepcional, con muy pocos casos descritos hasta la fecha². Describimos el caso clínico de una mujer con un TCG de hipófisis posterior asociado a una enfermedad de Cushing.

Mujer nacida en 1954 con historia de hipertensión arterial esencial, diabetes mellitus tipo 2 y meningioma frontal derecho. En 2014 se diagnosticó de síndrome de Cushing a raíz de cambios en el fenotipo facial, hipotrofia muscular, aumento del perímetro abdominal, hematomas espontáneos y fracturas costales. No presentaba estrías. Su perímetro abdominal era de 101 cm, peso 60,9 kg, talla 154 cm y presión arterial 165/88 mmHg. El estudio funcional bioquímico sugirió un hipercortisolismo endógeno de origen hipofisario [cortisol libre urinario (CLU) 318 µg/g creatinina (Cr) (normal 10-100 µg/g Cr)]. Sin embargo, la resonancia hipofisaria fue normal. Un cateterismo de senos petrosos confirmó el origen hipofisario del hipercortisolismo. Se decidió realizar una hemihipofisectomía endoscópica endonasal en mayo de 2016. Durante el acto quirúrgico se observó una hipófisis nor-

mal, pero con una zona posterolateral fibrosa sospechosa, que se resecó. El estudio anatomopatológico informó de la presencia de glándula hipofisaria normal en uno de los bloques. En el otro, se observó la presencia de un tumor fibrilar compuesto de células fusiformes, epiteloideas y granulares, positivas para proteína S-100 y TTF-1, compatible con TCG. Se observaron en su interior nidos de células positivas para sinaptofisina y ACTH, concordantes con un corticotropinoma (fig. 1).

La cirugía no fue curativa (CLU 311,6 µg/g Cr a los 2 meses de la intervención), por lo que se decidió tratamiento con radioterapia estereotáxica fraccionada (dosis acumulada de 51 Gy en 28 sesiones) y se inició ketoconazol adyuvante (800 mg cada 24 h) en julio de 2016. Pese a las dosis altas de ketoconazol no se consiguió normalizar las concentraciones de cortisol libre en orina, por lo que se sustituyó ketoconazol por pasireótida 20 mg cada 28 días. El tratamiento con pasireótida normalizó las concentraciones de CLU (87 µg/g Cr) y redujo significativamente las concentraciones circulantes de ACTH y de cortisol sérico, pero deterioró el control metabólico de la diabetes previa que presentaba la paciente. Tras 3 años de tratamiento con pasireótida y 4 años tras la radioterapia, la paciente presenta criterios bioquímicos de enfermedad controlada, con gran mejoría clínica. La dosis actual de pasireótida es de 20 mg cada 6 semanas. La diabetes se controla adecuadamente con sitagliptina 100 mg/día y dapagliflocina 10 mg/día.

La coexistencia de adenomas hipofisarios funcionantes y de tumores de hipófisis posterior es excepcional. En una revisión publicada recientemente², se describen 10 casos de tumores de hipófisis posterior asociados a hipercortisolismo, 7 de ellos con histología de pituitomas y 3 con un TCG. Actualizando los datos reportados por dicha revisión, en el momento de la escritura de este caso clínico, existen 9 pituitomas asociados a síndrome de Cushing y tan solo 2 TCG, el reportado por Zhang et al.³ y el actual caso